ARWR — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Income: $30.8 million ($0.22 per share), a significant improvement from a net loss of $173.1 million ($1.39 per share) in Q1 2025.
• Revenue: $264 million, primarily driven by collaboration agreements with Sarepta ($229 million) and Novartis ($34 million).
• Operating Expenses: Increased to $223 million from $164 million year-over-year, attributed to higher R&D ($40 million) and SG&A expenses ($19 million).
• Cash and Investments: $917 million as of December 31, 2025, excluding recent financing transactions and milestone payments.

2. Strategic Updates and Business Highlights

• Regulatory Approvals: FDA approved REDEMPLO for treating familial chylomicronemia syndrome (FCS) on November 18, 2025; also received approvals in Canada and China.
• Product Launch: REDEMPLO launched independently in the U.S. with over 100 prescriptions received within the first 10 weeks, showing promising uptake.
• Pipeline Development: Advancements in cardiometabolic programs including ongoing Phase III studies for plozasiran (SHTG) and promising interim results from obesity treatments ARO-INHBE and ARO-ALK7.
• CNS Programs: Progress in CNS portfolio with ARO-MAPT targeting tauopathies and SRP-1005 for Huntington's disease, leveraging a new delivery system for blood-brain barrier penetration.

3. Forward Guidance and Outlook

• Commercial Sales: Anticipated growth from REDEMPLO and potential launches of plozasiran in SHTG and other candidates.
• Upcoming Data Releases: Expect top-line data from Phase III studies (SHASTA-3 and SHASTA-4) in Q3 2026, and further results from obesity and CNS programs throughout the year.
• Long-term Vision: Arrowhead aims to become cash flow positive and self-sustaining through commercial sales, with multiple potential launches expected in the coming years.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Significant rise in operating expenses could pressure profitability despite revenue growth.
• Market Competition: The competitive landscape for obesity treatments and cardiometabolic drugs remains intense, with established players like Lilly offering similar products at competitive prices.
• Prescription Conversion: While initial prescription numbers are encouraging, the actual conversion to paid drug remains uncertain, and the company acknowledges the need for ongoing payer negotiations and patient education.

5. Notable Q&A Insights

• Patient Dynamics: Majority of early prescriptions for REDEMPLO come from APOC3-naive patients, with switches driven by efficacy and safety concerns.
• FDA Discussions: Plans to engage with the FDA regarding the development path for obesity treatments are expected mid-2026.
• ARO-DIMER-PA Expectations: The company is looking for LDL and triglyceride reductions in the upcoming data that would support further development.
• Pricing Strategy: Discussions on pricing for obesity treatments are premature, with a focus on understanding the biology and efficacy before setting prices.
• CNS Platform Confidence: Confidence in the CNS targeting platform will increase with successful clinical data from ARO-MAPT and SRP-1005.

Overall, Arrowhead Pharmaceuticals is positioned for growth with significant advancements in its pipeline and a strong financial foundation, though it faces challenges related to competition and the need for effective commercialization strategies.